Overview: Bayer is facing yet another lawsuit over their drospirenone-containing birth control pills, Yaz and yasmin. The lawsuit was filed on behalf of three women from Colorado, Pennsylvania and Ohio. Although their locations differ, the lawsuit alleges that they all experienced blood clot complications as a result of taking Yaz or Yasmin.
- Three women have filed a joint lawsuit in California alleging Yaz and Yasmin are defective drugs that caused blood clots
- Two of the Plaintiffs suffered from deep vein thrombosis and one experienced a pulmonary embolism, a potentially-fatal condition
- The FDA has warned that women taking Yaz, Yasmin, Ocella and other birth control pills containing drospirenone may be three times as likely to develop a blood clot
Product: Yaz®, Yasmin® (Drospirenone and Ethinyl Estradiol)
Manufacturer: Bayer AG
Side Effects & Complications
- Blood Clots
- Pulmonary Embolism (PE)
- Deep Vein Thrombosis (DVT)
- Gallbladder Damage
- Heart Attacks
Lawsuit Says Yaz, Yasmin Caused Deep Vein Thrombosis and Pulmonary Embolism
The Plaintiffs filed their complaint on December 13, 2012 in the Superior Court of the Stats of California. The suit named Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc. and McKesson Corporation as Defendants in the case. All of the Plaintiffs say that they suffered severe complications after taking Yaz or Yasmin. Two of the women suffered deep vein thrombosis, where a blood clot forms in the deep veins of the legs. The third woman alleges that the oral contraceptive led to a pulmonary embolism, where a part of a blood clot can break away and enter the bloodstream, eventually becoming trapped in the lungs; this is a potentially fatal condition. The suit, like so many others filed before them, hold the manufacturers responsible for these injuries.
Bayer Facing Thousands of Lawsuits Over Yaz and Yasmin
More than 12,000 lawsuits have been filed against Bayer over Yaz and Yasmin. According to the company’s third quarter stockholder report, it has spent $750 million to settle over 3,400 cases alleging the pills caused blood clots. With a remaining 8,000 cases alleging deep vein thrombosis, pulmonary embolism, gallbladder disease and sudden death, it does not appear that Bayer will be out of Yaz litigation anytime in the near future. In fact, as more research is conducted it only appears that Yaz and Yasmin lawsuits will continue to mount. Last April, the FDA updated the label on the drugs to warn about the risk of blood clots, stating that some studies even suggested a three-fold increased risk. The agency also funded a recent study showing that women taking Yaz, yasmin and other drospirenone-containing contraceptives are 77 percent more likely to suffer from a venous thromboembolic event and twice as likely to experience an arterial thromboembolic event, where a blood clot becomes lodged in a vein or artery, respectively.